Live Chat

交易 Vir Biotechnology VIR

VirBiotechnology實時圖表

金融工具基礎知識

Weekly Search
Weekly
Daily
日期  關閉 更改 更改(%): 開倉

最新新聞

Christine Voong 2024 Nov 21, 10:18

華為晶片Ascend 910C計劃2025年量產,面臨美國禁令與台積電供應挑戰

Christine Voong 2024 Nov 21, 08:05

黃金價格走勢:俄烏衝突推動黃金價格上漲,美元與利率預期施壓金價

Christine Voong 2024 Nov 21, 04:13

美元匯率回升,美元指數攀升至一年高點,市場焦點轉向川普政策與聯準會

So Ze Dong 2024 Nov 20, 16:00

11月21日財經:輝達財報亮眼卻股價下跌,美股指數表現平平

Christine Voong 2024 Nov 20, 10:20

歐洲股市開盤上漲,原油價格小幅上漲,市場聚焦經濟數據與俄烏局勢

Christine Voong 2024 Nov 20, 08:27

比特幣價格走勢:創新高後持穩於92,000美元,市場聚焦川普政策

Christine Voong 2024 Nov 20, 04:50

美股指數波動:Nvidia推動標普500指數與納斯達克指數上漲,市場情緒回升

So Ze Dong 2024 Nov 20, 01:00

11月20日財經:輝達主導科技股領漲,俄烏局勢升溫避險情緒短暫回升

聯絡方式

點差

0.06

點差(%)

0.9119 %

槓桿

1:10

隔夜利息(買入)

-0.0597 %

隔夜利息(賣出)

-0.0292 %

貨幣

USD

交易時間

市場開放

星期四

14:31 - 20:59

星期一

14:31-20:59

星期二

14:31-20:59

星期三

14:31-20:59

星期五

14:31-20:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

954399552

流通股份

137720000

收益日期(下一個)

0000-00-00

現金殖利率 

除息日

遠期年股息率

0

遠期年現金殖利率

0

每股盈餘

-3.87

了解有關此金融工具的詳細資訊

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

相關工具

資產
出售
購買
更改(%):
查看所有金融工具
Trustpilot
Live Chat